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Adipose tissue at the crossroads 
in the development of the 
metabolic syndrome, inflammation 
and atherosclerosis
Tecido adiposo na encruzilhada no desenvolvimento da 
síndrome metabólica, inflamação e aterosclerose
Bernardo Léo Wajchenberg1, 2, Marcia Nery1,  
Maria Rosaria Cunha1, Maria Elizabeth Rossi da Silva1
ABSTRACT
The authors analyze insulin resistance, the metabolic syndrome and endothelial dysfunction as 
consequence of a common antecedent, a low grade inflammation, indicating that in obesity the-
re is a chronically activated inflammatory state of the adipose tissue. Furthermore, the inflam-
matory signaling is discussed according to the adipose tissue depot, visceral or subcutaneous. 
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RESUMO
Os autores analisam a resistência à insulina, a síndrome metabólica e a disfunção endotelial 
como consequência de um antecedente comum, a inflamação de baixo nível, o que mostra que 
a obesidade é um estado inflamatório cronicamente ativado do tecido adiposo. Discute-se, aqui, 
a sinalização inflamatória de acordo com a localização do tecido adiposo subcutâneo ou visceral. 
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The clustering of dyslipidemia, hypertension and glucose intolerance, predominantly in overweight 
individuals, at risk of heart disease, has been received 
many names, including syndrome X and metabolic 
syndrome. In Reaven’s original description of the syn-
drome, a central etiological role was attributed to in-
sulin resistance and/or hyperinsulinemia, in part deter-
mined by obesity (1), and this assumption has become 
the dominant paradigm for the metabolic syndrome (2). 
However, there is a substantial contradiction in such as-
sociation. In part because of measurement problems 
and the fact that though “insulin resistance” may be 
important, it provides an insecure foundation for the 
metabolic syndrome, to a level in which it is no longer 
considered a useful (or at least measurable) criterion. A 
number of associated clinical features congregate in in-
dividuals who are at increased risk of heart disease. They 
cluster together for a reason, and it is important to seek 
an explanation for this at a pathophysiological level (3). 
Regarding the novel markers as responsible for as-
sociations to insulin resistance, there is a possibility that 
they may help to explain relations which seem biologi-
cally implausible. In particular, the coexistence of mi-
croalbuminuria with insulin resistance in diabetic and 
non-diabetic individuals as well as the association of in-
sulin resistance with other measures of endothelial dys-
function are difficult to be conceptualize as a cause-and-
consequence relationship. Although there is a possibility 
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
146 Arq Bras Endocrinol Metab. 2009;53/2
of a reverse etiology, whereby insulin resistance is a con-
sequence of endothelial dysfunction, both insulin resis-
tance and endothelial dysfunction are consequences of 
a common etiological mechanism (4). In a population 
of healthy adults, Yudkin and cols. (5) reported good 
correlations with metabolic syndrome variables, includ-
ing insulin resistance and endothelial dysfunction, with 
a score of low grade inflammation derived from circu-
lating concentrations of cytokines TNF-α and interleu-
kin-6 (IL-6) and the acute-phase markers C-reactive 
protein (CRP) and fibrinogen, suggesting that 35% of 
the variance of the measures comprising the metabolic 
syndrome could be “explained by a state of low-grade 
inflammation”. The findings brought, for the first time, 
the possibility that the association between insulin resis-
tance and the components of the metabolic syndrome 
could be a consequence of their common outcomes of 
a low-grade inflammation state. 
Furthermore, there were strong and consistent rela-
tionships with anthropometric measures of obesity and 
central fat distribution, as about 20% of the variance 
of the acute-phase markers could be explained, statisti-
cally, on the basis of adiposity (5). Many prospective 
studies have shown that excess of body fat in the upper 
(central or abdominal) part of the body is more often 
correlated to the features of the metabolic syndrome. In 
contrast, individuals with fat stored in gluteal-femoral 
or peripheral depots (lower-body obesity) or female-
type of fat distribution have a lower risk of morbidity 
from these metabolic disturbances (6). As reviewed by 
Karelis and cols. (7), approximately 20% of the general 
population can be categorized as obese but metaboli-
cally healthy, presenting low visceral fat with high body 
mass index (BMI) and high insulin sensitivity. Quite the 
opposite, 18% of the population were found to have a 
normal body weight or were slightly overweight (meta-
bolically obese normal weight), with high visceral fat, 
low BMI, low insulin sensitivity and high liver fat dis-
playing severe metabolic abnormalities. Recently, Stefan 
and cols. (8), found, in a large population, that while 
the measurement of visceral fat provides a powerful tool 
to discriminate between insulin-sensitive and insulin-re-
sistant, subjects within normal weight and overweight 
range. In the obese spectrum, the predictive effect of 
visceral fat was relatively weak. Visceral fat was lower 
in obese-insulin sensitive group than the obese-insulin 
resistant group, but the difference was not statistically 
significant, maybe unexpected considering the data col-
lected by Wajchenberg and cols. (6). Nevertheless, in 
agreement with our study, Stefan and cols. (8) agree 
that excess of fat, particularly visceral fat, when in-
flamed, affects insulin sensitivity in large scale; however, 
with increased total adiposity, factors beyond excess of 
visceral fat may become more important for regulating 
insulin sensitivity, such as the liver and the muscle. 
As suggested by Yudkin and cols. (2,5), a more 
likely paradigm for the metabolic syndrome seems to 
be that of adipose tissue-generated molecules initiat-
ing a state of low-grade inflammation, with the known 
actions of these pro-inflammatory cytokines resulting 
in the combined metabolic, hemodynamic and vascu-
lar consequences of this state. In this paradigm, insulin 
resistance merely becomes another consequence of this 
low grade inflammatory state. 
Hotamisligil and cols. (9) were the first to describe 
the molecular connection between inflammation and 
obesity when TNF-α, an inflammatory cytokine, was 
found to be expressed in adipose tissue in obese ani-
mal models, contributing to inhibition of insulin sig-
naling pathways which has led to the exploration and 
characterization of several other adipokines with similar 
metabolic functions (10). The fact that these cytokines 
inhibit the effect of insulin on endothelial cells (2) may 
additionally contribute to insulin resistance by limiting 
nutrient-induced increase in nutritive capillary flow to 
muscle, as well as muscle glucose uptake. 
Adipokines, the bioactive mediators produced in 
the adipose tissue, include not only adipocytes but 
also other cells that are present in fat tissue. Although 
adipocytes can produce almost all known adipokines, 
pre-adipocytes, as well as macrophages and endothelial 
cells of adipose tissue also contribute to adipokine pro-
duction. Some of these substances are specifically, or 
abundantly, produced by fat tissue (leptin, adiponectin, 
visfatin, apelin, resistin) whereas others are clearly not 
specific for adipose tissue since they are not exclusively 
or preferentially expressed there and have been previ-
ously identified and characterized as belonging to other 
families of substances [MCP-1, TNF-α, IL-6, PAI-1, 
angiotensinogen, 11β-hydroxysteroid dehydrogenase 
(11β-HSD-1, which converts inactive cortisone into 
active cortisol) and endocannabinoids] (11). 
The adipokines, they are more than 50 different 
types currently recognized, act in a paracrine, autocrine 
and endocrine way influencing the metabolism of lipid, 
glucose homeostasis, in some cardiovascular risk fac-
tors, such as hypertension, as well as thrombotic and 
inflammatory processes. The functions of adipokines 
Adipose tissue
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
147Arq Bras Endocrinol Metab. 2009;53/2
were recently extended far beyond metabolism to areas 
such as immunity, tumoral processes, angiogenesis and 
bone formation. 
It is important to distinguish visceral from subcu-
taneous adipose tissue in connection with the expres-
sion of the different adipokines by their implications 
in the development of the metabolic syndrome. The 
visceral fat plays an important role in the pathogenesis 
of cardiovascular diseases since it expresses many com-
ponents strongly involved as cardiovascular risk factors, 
such as IL-6, PAI-1 and glucocorticoids, while the sub-
cutaneous fat produces mostly protective substances 
such as leptin and adiponectin and is less sensitive to 
glucocorticoids (12). Furthermore, adipokines released 
from visceral fat have, via portal vein, a direct access to 
the liver, and, therefore, a huge impact on the inflam-
matory process. 
The primary mechanisms of action of adipose tissue-
produced inflammatory adipokines can be referred to 
according to the anatomic location of fat depot in which 
the adipokines are produced. Thus, adipokines released 
by the visceral depot would exert a greater effect on 
hepatic carbohydrate and lipid metabolism, stimulating 
hepatic release of acute phase response proteins in the 
liver (as CRP, an unspecific acute phase reactant that 
serves as an indicator of systemic inflammation) besides 
the autocrine/paracrine effects on the depot. Adipok-
ines produced by the subcutaneous depot would mainly 
affect locally the adipose cell develop ment and function 
(autocrine/paracrine effects) and exert systemic effects 
on, for example, skeletal muscle. The former may repre-
sent the mechanism whereby inflammatory adipokines 
induce hepatic insulin resistance and chronic systemic 
inflammation, as the latter diminish adipose tissue stor-
age of lipids, leading to ectopic fat accumulation in the 
liver and skeletal muscle (13). 
Many adipokines such as MCP-1, also known as 
C-C motif chemokine ligand 2 (CCL2), TNF-α and 
resistin (which function in humans is not clear yet), se-
creted by adipocytes from obese subjects can promote 
macrophage infiltration and accumulation in adipose 
tissue and subendothelial space. It has been confirmed 
by recent studies that showed the association of abdomi-
nal obesity with an increased amount of macrophages 
in adipose tissue (14). These macrophages are also im-
plicated in the secretion of a panel of inflammatory cy-
tokines (TNF-α, IL-6, MCP-1, PAI-1) acting in a para-
crine and endocrine manner, finally causing a state of 
permanent low-grade inflammation in obese subjects. 
The MCP-1 (CCL2) receptor, C-C motif chemokine 
receptor 2 (CCR2), from other CC chemokine recep-
tors present in the adipose tissue, plays a more notewor-
thy role in the regulation of monocyte and macrophage 
recruitment, besides being necessary for macrophage-
dependent inflammatory responses. This inflammatory 
state is implicated in cardiovascular disease, favoring 
endothelial insults and atheromatous changes (15). In 
Figure 1, the association between visceral adipose mass, 
secretion of inflammatory adipokines, insulin resistance 
and the metabolic syndrome is shown. 
Figure 1. Association between visceral adipose mass, secretion of inflammatory cytokines, insulin resistance and the metabolic syndrome.
↑ Visceral fat Atherogenesis
Endothelial
dysfunction
Adipocytes
FFA
Acute-phase
lipids
Acute-phase
proteins (CRP)
Based on Schmidt and Duncan. Clin Chem LAb Med. 2003;41:1120.
Insulin
resist.
↑ Pro-inflammatory cytokines
TNF-α, IL-6, SAA3 etc.
(autocrime, paracrine and
epicrine actions) 
Adipocytes + macrophages
Adipose tissue
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Adipokines are involved in every step of the ather-
omatous process which begins with inflammatory 
changes of the vascular wall. The vascular insult is first 
caused by cytokines like TNF-α and IL-6, leading to 
increased expression of adhesion molecules such as in-
tercellular adhesion molecule 1 (ICAM-1) and vascular 
cell adhesion molecule-1 (VCAM-1) which enhance 
monocyte adhesion to the endothelium. At the same 
time, MCP-1 (CCL2) secreted by adipocytes and by in-
jured endothelial cells not only increases the migration 
of monocytes but also favors their transformation into 
foam cells. These foam cells secrete metalloproteinases 
that may lead to plaque rupture. Because of its low 
levels in obesity, the protective effects of adiponectin 
against plaque formation are decreased. Adiponectin 
is a specific white adipose tissue-derived protein, with 
anti-inflammatory/antiatherogenic properties such as 
decreasing the expression of adhesion molecules, de-
creasing monocyte adhesion to endothelial cells, de-
creasing uptake of oxidized low-density lipoprotein 
(LDL), decreasing foam cell formation, and decreasing 
proliferation and migration of vascular smooth muscle 
(11). Adiponectin increases insulin sensitivity, increases 
smooth muscle glucose uptake and free fatty acid oxi-
dation, decreases hepatic glucose production and de-
creases intracellular triglycerides (16). Furthermore, 
obesity is also linked to a hypercoagulable state caused 
by increase in circulating levels of procoagulant factors 
such as tissue factor, fibrinogen, von Willebrand factor 
and factor VII. In addition, many circulating cytokines 
elevated in obesity will cause endothelial activation, 
leading to platelet activation and plug formation (17). 
The inhibition of fibrinolysis caused by an increased 
level of PAI-1 (particularly high in obesity and diabe-
tes) is another component of this hypercoagulable pro-
cess, favoring thrombus formation upon ruptured ath-
erosclerotic plaques (18). 
Hence, the state of chronic low-grade inflammation 
of obesity is probably the link between the different com-
ponents of the metabolic syndrome and atherosclerosis. 
It has been shown that distinct inflammatory path-
ways that occur in the adipocyte can be initiated by ex-
tracellular mediators, such as cytokines and lipids, or in-
tracellular stresses, such as endoplasmic reticulum stress 
or excessive production of reactie oxygen species by the 
mitochondria. Signals from these mediators converge 
to inflammatory signaling pathways, including the ki-
nases JNK and inhibitor of NF-κβ kinase (IKKβ). These 
pathways induce the production of additional inflam-
matory mediators through transcriptional regulation as 
well as the inhibition of insulin signaling (19). Recently 
it has been found that different inflammatory pathways 
occur in the different adipose tissue depots, the omen-
tal tissue with increased NF-κβ and increased JNK ac-
tivity in subcutaneous abdominal adipose tissue. Addi-
tionally, NF-κβ was shown to be influenced by obesity 
and diabetes status. These data suggest that NF-κβ may 
play a more predominant central role in inflammatory-
related metabolic disease in comparison to JNK (20) 
(Table 1). These findings are in accordance to the well 
known observations that visceral adipose tissue, which 
includes the omental tissue, is closely associated with 
sub-clinical inflammation, insulin resistance and type 2 
diabetes mellitus (12). 
Table 1. Distinct inflammatory signalling pathways according to the adipose 
tissue depot
Obese non-diabetics 
Adipose tissue depot 
JNK NFκB
activities 
Omental ↓ ↑
Abdominal subcutaneous ↑
Obese type 2 diabetics 
Omental ↑
Abdominal subcutaneous ↓
Source: Kusminski and cols. Diabetologia. 2007;50 Suppl 1: Abstract 153. (20)
In corroboration of genetic evidence in mice with 
loss of inflammatory mediators or signaling molecules 
prevents insulin resistance (19), pharmacological tar-
geting of inflammatory pathways also improves insu-
lin action. Effective treatment has been demonstrated 
both with inhibitors of inflammatory kinases and with 
agonists of relevant transcription factors. The classical 
drug, salicylates, in high doses, including sodium salicy-
late and aspirine 4 to 10g of salicylate per day) was used 
to treat inflammatory conditions such as rheumatic fever 
and rheumatoid arthritis. The high doses are thought 
to inhibit NF-κβ and its upstream activator, the IκB 
kinase β (IKKβ), as opposed to working through cy-
clooxygenases (COXs 1 and 2) – the classical targets 
of nonsteroidal anti-inflammatory drugs (NSAIDs) – in 
doses equivalent to 650 mg/day of aspirine, while dos-
es utilized in the prevention of coronary heart disease 
– usually from 81 to 100 mg/day to decrease platelet 
aggregation – inhibit COX-1. High doses of salicylates 
also lower blood glucose concentrations, but are not 
used in present biomedical science for obvious reasons. 
In obese rodents and diabetic humans, high doses of 
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salycilates reverse hyperglycemia, insulin resistance and 
dyslipidemia by sensitizing insulin signaling through 
inhibition of IKKβ (in liver, but not in muscle) and 
other possible kinases (21). 
Further research is needed to fully understand the 
pathophysiology of the adipokines and to determine 
potential targets for new therapeutic approaches. For 
now, it has been shown that lifestyle changes leading to 
weight loss are associated with an improvement of en-
dothelial functions and reduction in circulating markers 
of inflammation (22,23). Interestingly, weight loss by 
surgical removal of visceral fat, but not by subcutaneous 
liposuction, is associated with significant decrease in cir-
culating CRP, IL-6, interleukin-18 (IL-18) and TNF-α 
(24). Moreover, the thiazolidinediones (TZDs), high 
affinity ligands of PPARγ, which are given clinically as 
insulin-sensitizing agents, likely improve insulin action 
through multiple mechanisms, including both activat-
ing lipid metabolism and reducing production of in-
flammatory mediators such as TNF-α. Because of the 
abundant expression of PPARγ in adipose tissue, pre-
dominantly in subcutaneous fat, it is generally thought 
that the induction of adipogenesis to recruit new small 
adipocytes, and thus improve adipose tissue lipid ac-
commodation and adiponectin secretion, accounts for 
most of the credible metabolic outcomes of thiazoli-
dinediones (TZDs) (13), though they also have anti-
inflammatory actions and inhibit the transcriptional 
activity of TNF-α promoter as well as antagonize the 
effects of exogenous administration of TNF-α in vivo 
and in vitro, independently of the adipogenic effect of 
the PPARγ agonist (25). It was shown that short-term 
pioglitazone therapy (45 mg/day for three weeks in 
obese with type 2 diabetes) improved insulin sensitivity 
in part by reducing adipose tissue macrophage content 
through lowering CCL2 mRNA and CCR2 mRNA ex-
pression in subcutaneous adipose tissue, which led to a 
decrease of macrophage content in 69% in comparison 
to control, resulting in less inflammation and, then, im-
proved insulin sensitivity (26). 
In addition to these cardiovascular and metabolic ef-
fects, the chronic low grade inflammation of obesity may 
also play a role in other inflammatory illnesses such as 
joint diseases and inflammatory bowel disease. It appears 
to be that adipose tissue and adipokines can no longer 
be regarded as completely innocent in arthritis because 
they modulate the expression of local synovial cytokines 
and matrix-degrading enzymes. They may, therefore, 
become an attractive target for new treatment (27). 
In conclusion, the adipose tissue is a highly active 
metabolic endocrine organ, being at the crossroads in 
the development of the metabolic syndrome, inflam-
mation and atherosclerosis. Obesity and particularly 
visceral fat excess is associated with insulin resistance, 
hyperglycemia, atherogenic dyslipidemia, hypertension 
as well as prothrombotic and pro-inflammatory states. 
Disclosure: No potential conflict of interest relevant to this article 
was reported.
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